




Instance: composition-en-b7ea2b843cac38255840aa11da0bbc43
InstanceOf: CompositionUvEpi
Title: "Composition for atosiban Package Leaflet"
Description:  "Composition for atosiban Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb7ea2b843cac38255840aa11da0bbc43)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - atosiban"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Atosiban SUN is and what it is used for </li>
<li>What you need to know before you are given Atosiban SUN </li>
<li>How Atosiban SUN will be given </li>
<li>Possible side effects </li>
<li>How to store Atosiban SUN </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What atosiban is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What atosiban is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Atosiban SUN contains atosiban. Atosiban SUN is used to delay the premature birth of your baby. 
Atosiban SUN is used in pregnant adult women, from week 24 to week 33 of the pregnancy. </p>
<p>Atosiban SUN works by making the contractions in your womb (uterus) weaker. It also makes the 
contractions happen less often. It does this by blocking the effect of a natural hormone in your body 
called  oxytocin  which causes your womb (uterus) to contract. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take atosiban"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take atosiban"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Atosiban SUN 
- If you are allergic to atosiban or any of the other ingredients of this medicine (listed in 
section 6). 
- If you are less than 24 weeks pregnant. 
- If you are more than 33 weeks pregnant. 
- If your waters have broken (premature rupture of your membranes) and you have completed 
30 weeks of your pregnancy or more. 
- If your unborn baby (foetus) has an abnormal heart rate. 
- If you have bleeding from your vagina and your doctor wants your unborn baby to be delivered 
straight away. 
- If you have something called  severe pre-eclampsia  and your doctor wants your unborn baby 
to be delivered straight away. Severe pre-eclampsia is when you have very high blood pressure, 
fluid retention and/or protein in your urine. 
- If you have something called  eclampsia  which is similar to  severe pre-eclampsia  but you 
would also have fits (convulsions). This will mean your unborn baby needs to be delivered 
straight away. 
- If your unborn baby has died. 
- If you have or could have an infection of your womb (uterus). 
- If your placenta is covering the birth canal. 
- If your placenta is detaching from the wall of your womb. 
- If you or your unborn baby have any other conditions where it would be dangerous to continue 
with your pregnancy. </p>
<p>Do not use Atosiban SUN if any of the above apply to you. If you are not sure, talk to your doctor, 
midwife or pharmacist before you are given Atosiban SUN. </p>
<p>Warnings and precautions 
Talk to your doctor, midwife or pharmacist before you are given Atosiban SUN 
- If you think your waters might have broken (premature rupture of your membranes). 
- If you have kidney or liver problems. 
- If you are between 24 and 27 weeks pregnant. 
- If you are pregnant with more than one baby. 
- If your contractions start again, treatment with Atosiban SUN can be repeated up to three more 
times. 
- If your unborn baby is small for the time of your pregnancy. 
- Your womb may be less able to contract after your baby has been born. This may cause 
bleeding. 
- If you are pregnant with more than one baby and/or are given medicines that can delay the birth 
of your baby, such as medicines used for high blood pressure. This may increase the risk of lung 
oedema (accumulation of fluid in the lungs). </p>
<p>If any of the above apply to you (or you are not sure), talk to your doctor, midwife or pharmacist 
before you are given Atosiban SUN. </p>
<p>Children and adolescents 
Atosiban SUN has not been studied in pregnant women less than 18 years old. </p>
<p>Other medicines and Atosiban SUN 
Tell your doctor, midwife or pharmacist if you are taking, have recently taken or might take any other 
medicines.  </p>
<p>Pregnancy and breast-feeding 
If you are pregnant and breast-feeding an earlier child, you should stop breast-feeding while you are 
given Atosiban SUN. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take atosiban"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take atosiban"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Atosiban SUN will be given to you in a hospital by a doctor, nurse or midwife. They will decide how 
much you need. They will also make sure the solution is clear and free from particles. </p>
<p>Atosiban SUN will be given into a vein (intravenously) in three stages:</p>
<ul>
<li>The first injection of 6.75 mg in 0.9 ml will be slowly injected into your vein over one minute. </li>
<li>Then a continuous infusion (drip) will be given at a dose of 18 mg per hour for 3 hours. </li>
<li>Then another continuous infusion (drip) at a dose of 6 mg per hour will be given for up to 
45 hours, or until your contractions have stopped. 
Treatment should last no longer than 48 hours in total. </li>
</ul>
<p>Further treatment with Atosiban SUN can be used if your contractions start again. Treatment with 
Atosiban SUN can be repeated up to three more times. </p>
<p>During treatment with Atosiban SUN, your contractions and your unborn baby s heart rate may be 
monitored. </p>
<p>It is recommended that no more than three re-treatments should be used during a pregnancy. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side 
effects seen in the mother are generally mild. There are no known side effects on the unborn or new-
born baby. </p>
<p>The following side effects may happen with this medicine: </p>
<p>Very common (may affect more than 1 in 10 people) 
- Feeling sick (nausea). </p>
<p>Common (may affect less than 1 in 10 people) 
- Headache. 
- Feeling dizzy. 
- Hot flushes. 
- Being sick (vomiting). 
- Fast heart beat. 
- Low blood pressure. Signs may include feeling dizzy or light-headed. 
- A reaction at the site where the injection was given. 
- High blood sugar. </p>
<p>Uncommon (may affect less than 1 in 100 people) 
- High temperature (fever). 
- Difficulty sleeping (insomnia). 
- Itching. 
- Rash. </p>
<p>Rare (may affect less than 1 in 1,000 people) 
- Your womb may be less able to contract after your baby has been born. This may cause 
bleeding. 
- Allergic reactions. </p>
<p>You may experience shortness of breath or lung oedema (accumulation of fluid in the lungs), 
particularly if you are pregnant with more than one baby and/or are given medicines that can delay the 
birth of your baby, such as medicines used for high blood pressure. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, midwife or pharmacist. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store atosiban"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store atosiban"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the label after EXP {MM/YYYY}. 
The expiry date refers to the last day of that month. </p>
<p>Store in a refrigerator (2 C - 8 C). Once the vial has been opened, the medicinal product must be used 
straight away. 
Store in the original package in order to protect from light. </p>
<p>Do not use Atosiban SUN if you notice particulate matter and discoloration prior to administration. </p>
<p>Do not throw away any medicines in wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Atosiban SUN contains 
- The active substance is atosiban. 
- Each vial of Atosiban SUN 6.75 mg/0.9 ml solution for injection contains atosiban acetate 
equivalent to 6.75 mg of atosiban in 0.9 ml. 
- The other ingredients are mannitol, hydrochloric acid 1M and water for injections. </p>
<p>What Atosiban SUN looks like and contents of the pack 
Atosiban SUN 6.75 mg/0.9 ml solution for injection is a clear, colourless solution without particles. 
One pack contains one vial containing 0.9 ml solution. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132 JH Hoofddorp 
The Netherlands </p>
<p>For any information about this medicinal product, please contact the local representative of the 
Marketing Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien/ / esk  republika/ 
Danmark/Eesti/ /Hrvatska/Ireland/ sland/ / 
Latvija/Lietuva/Luxembourg/Luxemburg/Magyarorsz g/ 
Malta/Nederland/Norge/ sterreich/Portugal/Slovenija/ 
Slovensk  republika/Suomi/Finland/Sverige 
Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132 JH Hoofddorp 
Nederland/Pays-Bas/Niederlande/ /Nizozemsko/ 
Nederlandene/ /Nizozemska/The Netherlands/Holland/ 
 /N derlande/Nyderlandai/Pays-Bas/Niederlande/ 
Hollandia/L-Olanda/Nederland/Niederlande/Pa ses Baixos/ 
Nizozemska/Holandsko/Alankomaat/Nederl nderna 
Tel./ ./tlf./ ./S mi/ ./Tlf./Puh./ 
+31 (0)23 568 5Deutschland 
Sun Pharmaceuticals Germany GmbH 
Hemmelrather Weg 51377 Leverkusen 
Deutschland 
tel. +49 214 403 Espa a 
Sun Pharma Laboratorios, S.L.<br />
Rambla de Catalunya 53-08007 Barcelona 
Espa a 
tel. +34 93 342 78 France 
Sun Pharma France 
11-15, Quai de Dion Bouton 
92800 Puteaux 
France 
tel. +33 1 41 44 44 Italia 
Sun Pharma Italia Srl 
Viale Giulio Richard, 1 
20143 Milano 
Italia 
tel. +39 02 33 49 07 Polska 
Ranbaxy (Poland) Sp. Z. o. o. 
ul. Kubickiego 02-954 Warszawa<br />
Polska 
tel. +48 22 642 07 Rom nia 
Terapia S.A. 
Str. Fabricii nr Cluj-Napoca, Jude ul Cluj 
Rom nia 
tel. +40 (264) 501 United Kingdom (Northern Ireland) 
Ranbaxy UK Ltd 
a Sun Pharma Company 
Millington Road Hyde Park, Hayes 3 
5th Floor 
UB3 4AZ HAYES 
United Kingdom 
tel. +44 (0) 208 848 8This leaflet was last revised in  </p>
<p>Other sources of information 
Detailed information on this medicine is available on the European Medicines Agency website: 
http://www.ema.europa.eu. </p>
<p>INSTRUCTION FOR THE HEALTHCARE PROFESSIONAL </p>
<p>The following information is intended for healthcare professionals only: 
(See also section 3) </p>
<p>Instructions for use 
Before using Atosiban SUN, the solution should be examined to ensure it is clear and free from 
particles. </p>
<p>Atosiban SUN is given intravenously in three successive stages:</p>
<ul>
<li>The initial intravenous injection of 6.75 mg in 0.9 ml is slowly injected into a vein over one 
minute. </li>
<li>A continuous infusion at a rate of 24 ml/hour is given for 3 hours. </li>
<li>A continuous infusion at a rate of 8 ml/hour is given for up to 45 hours, or until the contractions 
of the uterus have subsided. </li>
</ul>
<p>The total duration of the treatment should be no more than 48 hours. Further treatment cycles of 
Atosiban SUN can be used should contractions recur. It is recommended that no more than three 
retreatments should be used during a pregnancy. </p>
<p>Package leaflet: Information for the user </p>
<p>Atosiban SUN 37.5 mg/5 ml concentrate for solution for infusion 
atosiban </p>
<p>Read all of this leaflet carefully before you are given this medicine because it contains important 
information for you. 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor, midwife or pharmacist. 
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 
effects not listed in this leaflet. See section 4.</p>         </div>"""      



Instance: composition-da-b7ea2b843cac38255840aa11da0bbc43
InstanceOf: CompositionUvEpi
Title: "Composition for atosiban Package Leaflet"
Description:  "Composition for atosiban Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpb7ea2b843cac38255840aa11da0bbc43)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - atosiban"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse </li>
<li>Det skal du vide, før du får Atosiban SUN </li>
<li>Sådan får du Atosiban SUN </li>
<li>Bivirkninger </li>
<li>Opbevaring </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What atosiban is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What atosiban is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Atosiban SUN indeholder atosiban. Atosiban SUN bruges til at modvirke for tidlig fødsel af dit barn. 
Atosiban SUN anvendes til gravide voksne kvinder fra uge 24 til uge 33 i graviditeten. </p>
<p>Atosiban SUN virker ved at gøre sammentrækningerne i livmoderen (uterus) mindre kraftige. Desuden 
nedsættes hyppigheden af sammentrækningerne. Dette sker, fordi atosiban blokerer virkningen i din 
krop af et naturligt hormon, der kaldes "oxytocin", som forårsager sammentrækninger i livmoderen. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take atosiban"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take atosiban"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du må ikke få Atosiban SUN 
- hvis du er allergisk over for atosiban eller et af de øvrige indholdsstoffer i Atosiban SUN 
(angivet i punkt 6) 
- hvis du har været gravid i under 24 uger 
- hvis du har været gravid i over 33 uger 
- hvis vandet er gået (ved for tidlig brist på fosterhinderne), og dette sker efter 30 ugers graviditet 
eller senere 
- hvis fosterets puls er unormal 
- hvis du oplever blødning fra skeden, og lægen beslutter, at fødslen skal sættes i gang med det 
samme 
- hvis du oplever alvorlig svangerskabsforgiftning (præeklampsi), og lægen beslutter, at fødslen 
skal sættes i gang med det samme. Alvorlig svangerskabsforgiftning er en tilstand med forhøjet 
blodtryk, væskeophobning og/eller protein i urinen 
- hvis du har fødekramper (eklampsi), der svarer til "alvorlig svangerskabsforgiftning", men 
desuden ledsaget af kramper. Dette vil betyde, at fødslen skal sættes i gang med det samme 
- hvis fosteret er dødt 
- hvis du har eller kan have infektion i livmoderen 
- hvis moderkagen dækker fødselsvejen </p>
<ul>
<li>hvis moderkagen er ved at løsne sig fra livmodervæggen </li>
<li>ved andre tilstande, hvor en fortsættelse af graviditeten anses for at være farlig for dig eller det 
ufødte barn. </li>
</ul>
<p>Du må ikke få Atosiban SUN, hvis noget af det ovenstående passer på dig. Hvis du er usikker, så 
spørg din læge, jordemoder eller apotekspersonalet, før du får Atosiban SUN. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, jordemoderen eller apotekspersonalet, før du får Atosiban SUN:</p>
<ul>
<li>hvis du tror, at fostervandet er gået (for tidlig brist på fosterhinderne) </li>
<li>hvis du har nyre- eller leverproblemer </li>
<li>hvis du er mellem 24 og 27 uger henne i graviditeten </li>
<li>hvis du er gravid med flere fostre (tvillinger, trillinger etc.) </li>
<li>hvis sammentrækningerne af livmoderen kommer igen, kan behandling med Atosiban SUN 
gentages op til tre gange mere </li>
<li>hvis fosteret er for lille i forhold til, hvor langt henne du er i graviditeten </li>
<li>når barnet er født, kan livmoderens evne til at trække sig sammen være nedsat. Dette kan give 
blødning </li>
<li>hvis du er gravid med flere fostre og/eller tager medicin, der kan forsinke fødslen, såsom 
lægemidler, der bruges mod forhøjet blodtryk. Dette kan øge risikoen for væskeansamling i 
lungerne (lungeødem). </li>
</ul>
<p>Hvis noget af det ovenstående passer på dig, eller hvis du er usikker, så spørg din læge, jordemoder 
eller apotekspersonalet, før du får Atosiban SUN. </p>
<p>Børn og unge 
Atosiban SUN er ikke undersøgt hos gravide kvinder under 18 år. </p>
<p>Brug af anden medicin sammen med Atosiban SUN 
Fortæl det altid til lægen, jordemoderen eller apotekspersonalet, hvis du bruger anden medicin eller 
har gjort det for nylig.  </p>
<p>Graviditet og amning 
Hvis du er gravid, men stadig ammer et ældre barn, skal du stoppe amningen, imens du får Atosiban 
SUN. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take atosiban"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take atosiban"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Du får Atosiban SUN på et hospital af en læge, sygeplejerske eller jordemoder. De vil vurdere, hvor 
meget du har brug for. De vil også sikre sig, at det sterile koncentrat er klar og fri for partikler. </p>
<p>Atosiban SUN gives i en vene (intravenøst) i tre trin:</p>
<ul>
<li>Den første indsprøjtning af 6,75 mg i 0,9 ml gives som en langsom indsprøjtning i en vene over 
1 minut. </li>
<li>Derefter gives der en uafbrudt infusion (drop) med en dosis på 18 mg/time over 3 timer. </li>
<li>Derefter gives der yderligere en uafbrudt infusion (drop) med en dosis på 6 mg/time i op til timer, eller indtil sammentrækningerne af livmoderen er stilnet af. 
Behandlingen må højst vare i 48 timer. </li>
</ul>
<p>Yderligere behandlinger med Atosiban SUN kan komme på tale, hvis sammentrækningerne af 
livmoderen opstår igen. Behandlingen med Atosiban SUN kan gentages op til tre gange mere. </p>
<p>Under behandling med Atosiban SUN vil dine sammentrækninger og dit ufødte barns puls 
sandsynligvis blive overvåget. </p>
<p>Det frarådes at foretage mere end tre genbehandlinger under en graviditet. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. De 
bivirkninger, som er set hos moderen, er generelt milde. Der kendes ingen bivirkninger for fosteret 
eller det nyfødte barn. </p>
<p>Følgende bivirkninger kan forekomme ved brug af denne medicin: </p>
<p>Meget almindelig (kan forekomme hos flere end 1 ud af 10 brugere) 
- kvalme </p>
<p>Almindelig (kan forekomme hos færre end 1 ud af 10 brugere) 
- hovedpine 
- svimmelhed 
- hedeture 
- opkastning 
- hurtig hjerterytme 
- lavt blodtryk, hvor et af symptomerne kan være svimmelhed 
- en reaktion på det sted, infusionen (drop) blev givet 
- højt blodsukker </p>
<p>Ikke almindelig (kan forekomme hos færre end 1 ud af 100 brugere) 
- feber 
- søvnløshed 
- kløe 
- udslæt </p>
<p>Sjælden (kan forekomme hos færre end 1 ud af 1.000 brugere) 
- når barnet er født, kan livmoderens evne til at trække sig sammen være nedsat. Dette kan give 
blødning 
- allergiske reaktioner </p>
<p>Du kan opleve åndenød eller væskeansamling i lungerne (lungeødem), især hvis du er gravid med flere 
fostre (tvillinger, trillinger etc.) og/eller får andre lægemidler, der kan forsinke fødslen, såsom 
lægemidler mod forhøjet blodtryk. </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, jordemoder eller apoteket. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store atosiban"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store atosiban"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Opbevares i køleskab (2°C - 8°C). Så snart hætteglasset er blevet åbnet, skal lægemiddel anvendes 
med det samme. </p>
<p>Opbevares i den originale yderpakning, for at beskytte mod lys. </p>
<p>Brug ikke Atosiban SUN, hvis der er tegn på partikler eller misfarvning inden indgivelsen. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Atosiban SUN indeholder 
- Aktivt stof: atosiban. 
- Hvert hætteglas med Atosiban SUN 6,75 mg/0,9 ml injektionsvæske, opløsning, indeholder 
atosibanacetat svarende til 6,75 mg atosiban i 0,9 ml. 
- Øvrige indholdsstoffer: mannitol, saltsyre 1M og vand til injektionsvæsker. </p>
<p>Udseende og pakningsstørrelser 
Atosiban SUN 6,75 mg/0,9 ml injektionsvæske er en klar, farveløs opløsning uden partikler. 
En æske indeholder et hætteglas indeholdende 0,9 ml opløsning. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132 JH Hoofddorp 
Nederlandene </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen. </p>
<p>België/Belgique/Belgien/България/Česká republika/ 
Danmark/Eesti/Ελλάδα/Hrvatska/Ireland/Ísland/Κύπρος/ 
Latvija/Lietuva/Luxembourg/Luxemburg/Magyarország/ 
Malta/Nederland/Norge/Österreich/Portugal/Slovenija/ 
Slovenská republika/Suomi/Finland/Sverige 
Sun Pharmaceutical Industries Europe B.V. 
Polarisavenue 2132 JH Hoofddorp 
Nederland/Pays-Bas/Niederlande/Нидерландия/Nizozemsko/ 
Nederlandene/Ολλανδία/Nizozemska/The Netherlands/Holland/ 
Ολλανδία/Nīderlande/Nyderlandai/Pays-Bas/Niederlande/ 
Hollandia/L-Olanda/Nederland/Niederlande/Países Baixos/ 
Nizozemska/Holandsko/Alankomaat/Nederländerna 
Tel./тел./tlf./τηλ./Sími/τηλ./Tlf./Puh./ 
+31 (0)23 568 5 
Deutschland 
Sun Pharmaceuticals Germany GmbH 
Hemmelrather Weg 51377 Leverkusen 
Deutschland 
tel. +49 214 403  </p>
<p>España 
Sun Pharma Laboratorios, S.L.<br />
Rambla de Catalunya 53-08007 Barcelona 
España 
tel. +34 93 342 78<br />
France 
Sun Pharma France 
11-15, Quai de Dion Bouton 
92800 Puteaux 
France 
tel. +33 1 41 44 44<br />
Italia 
Sun Pharma Italia Srl 
Viale Giulio Richard, 1 
20143 Milano 
Italia 
tel. +39 02 33 49 07<br />
Polska 
Ranbaxy (Poland) Sp. Z. o. o. 
ul. Kubickiego 11<br />
02-954 Warszawa<br />
Polska 
tel. +48 22 642 07<br />
România 
Terapia S.A. 
Str. Fabricii nr Cluj-Napoca, Judeţul Cluj 
România 
tel. +40 (264) 501<br />
United Kingdom (Northern Ireland) 
Ranbaxy UK Ltd 
a Sun Pharma Company 
Millington Road Hyde Park, Hayes 3 
5th Floor 
UB3 4AZ HAYES 
United Kingdom 
tel. +44 (0) 208 848 8 
Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu/. </p>
<p>VEJLEDNING TIL SUNDHEDSPERSONALET </p>
<p>Nedenstående oplysninger er til læger og sundhedspersonale: 
(Se også punkt 3) </p>
<p>Instruktioner for brug 
Inden Atosiban SUN anvendes, skal opløsningen undersøges visuelt for at sikre, at den er klar og fri 
for partikler. </p>
<p>Atosiban SUN gives intravenøst i tre successive stadier:</p>
<ul>
<li>Den indledende intravenøse injektion på 6,75 mg i 0,9 ml injiceres langsomt i en vene over 1 
minut. </li>
<li>En uafbrudt infusion på 24 ml/time gives i 3 timer. </li>
<li>En uafbrudt infusion på 8 ml/time gives i op til 45 timer, eller indtil livmoderens 
sammentrækninger er aftaget. </li>
</ul>
<p>Behandlingen må højst vare 48 timer i alt. Yderligere behandlingscykler med Atosiban SUN kan 
bruges, hvis sammentrækningerne af livmoderen opstår igen. Det frarådes at foretage mere end tre 
genbehandlinger under en graviditet. </p>
<p>Indlægsseddel: Information til brugeren </p>
<p>Atosiban SUN 37,5 mg/5 ml koncentrat til infusionsvæske, opløsning 
atosiban </p>
<p>Læs denne indlægsseddel grundigt, inden du får dette lægemiddel, da den indeholder vigtige 
oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen, apotekspersonalet eller jordemoderen, hvis der er mere, du vil vide. 
- Kontakt lægen eller apotekspersonalet, hvis en bivirkning bliver værre, eller du får bivirkninger, 
som ikke er nævnt her. Se punkt 4. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-b7ea2b843cac38255840aa11da0bbc43
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for atosiban Package Leaflet for language en"
Description: "ePI document Bundle for atosiban Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-b7ea2b843cac38255840aa11da0bbc43"
* entry[0].resource = composition-en-b7ea2b843cac38255840aa11da0bbc43

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb7ea2b843cac38255840aa11da0bbc43"
* entry[=].resource = mpb7ea2b843cac38255840aa11da0bbc43
                            
                    
Instance: bundlepackageleaflet-da-b7ea2b843cac38255840aa11da0bbc43
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for atosiban Package Leaflet for language da"
Description: "ePI document Bundle for atosiban Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-b7ea2b843cac38255840aa11da0bbc43"
* entry[0].resource = composition-da-b7ea2b843cac38255840aa11da0bbc43

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpb7ea2b843cac38255840aa11da0bbc43"
* entry[=].resource = mpb7ea2b843cac38255840aa11da0bbc43
                            
                    



Instance: mpb7ea2b843cac38255840aa11da0bbc43
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Atosiban SUN 6.75 mg/0.9 ml solution for injection"
Description: "Atosiban SUN 6.75 mg/0.9 ml solution for injection"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/13/852/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Atosiban SUN 6.75 mg/0.9 ml solution for injection"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: b7ea2b843cac38255840aa11da0bbc43ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "atosiban"

* status = #current
* mode = #working

* title = "List of all ePIs associated with atosiban"

* subject = Reference(mpb7ea2b843cac38255840aa11da0bbc43)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#atosiban "atosiban"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-b7ea2b843cac38255840aa11da0bbc43) // atosiban en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-b7ea2b843cac38255840aa11da0bbc43) // atosiban da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-b7ea2b843cac38255840aa11da0bbc43
InstanceOf: List

* insert b7ea2b843cac38255840aa11da0bbc43ListRuleset
    